PI
MCRB icon

Pennant Investors’s Seres Therapeutics MCRB Stock Holding History

Pennant Investors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,615
Closed -$212K – 33
2024
Q2 		$212K Hold
14,615
– – 0.06% 36
2024
Q1 		$226K Hold
14,615
– – 0.06% 41
2023
Q4 		$409K Buy
+14,615
New +$384K 0.09% 28

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Pennant Investors's MCRB Position: Q3 2024 in Review

Pennant Investors sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 14,615 shares — an estimated $212K sold.

Pennant Investors first reported a position in MCRB in Q4 2023 and held it in 3 quarters. The position peaked at $409K in Q4 2023. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Pennant Investors reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 14,615 Seres Therapeutics shares in Q3 2024, an estimated $212K.
  • Pennant Investors first reported a position in Seres Therapeutics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Seres Therapeutics position peaked at $409K in Q4 2023.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.